1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,600 | 22,000 | 28.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| Mo | DUALITYBIO-B (09606): 2026 INTERIM REPORT | 1 | HKEx | ||
| 28.08. | DualityBio and Genentech to Develop Next-Gen ADCs on Novel Payload Platform | 7 | Contract Pharma | ||
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.08. | DUALITYBIO-B (09606): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 28.08. | Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact | 14 | FierceBiotech | ||
| 28.08. | DualityBio partners with Genentech on cancer drug development | 24 | Investing.com | ||
| 28.08. | DualityBio und Genentech schließen milliardenschweren Pakt zur Entwicklung von Krebsmedikamenten | 25 | Investing.com Deutsch | ||
| 28.08. | Duality Biotherapeutics Inc.: DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform | 591 | PR Newswire | Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical... ► Artikel lesen | |
| 28.08. | DUALITYBIO-B (09606): INSIDE INFORMATION - GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH, INC. TO DEVELOP NEXT-GENERATION ... | 1 | HKEx | ||
| 14.08. | DUALITYBIO-B (09606): DATE OF BOARD MEETING | 2 | HKEx | ||
| 29.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 7 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): (1) CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; (2) WAIVER FROM STRICT COMPLIANCE WITH RULES ... | 6 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): GRANT OF RESTRICTED SHARE UNITS UNDER THE 2025 SHARE SCHEME | 1 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 12.06. | DUALITYBIO-B (09606): ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE | 2 | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB ... | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | - | HKEx |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,25 | 0,00 % | BioNTech-Aktie: Analysten sehen wieder mehr Potenzial | Bei BioNTech war in den vergangenen Wochen einiges los. Ende August sorgte der Stopp einer mRNA-Studie bei Darmkrebs für einen kräftigen Rücksetzer, nur wenige Wochen später kamen aus einem anderen... ► Artikel lesen | |
| MODERNA | 173,76 | +0,13 % | Moderna-Aktie mit +35% - steht der Ausbruch bevor? | Die Moderna-Aktie hat gestern +12,27% zugelegt und notiert inzwischen bei 172,94 US$. Damit erreicht der Kurs eine entscheidende Widerstandszone. Während RSI und MACD eine starke Aufwärtsdynamik bestätigen... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,560 | -0,21 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,263 | 0,00 % | Defence Therapeutics Inc.: Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities | Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 39,790 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results |
- Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,330 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,00 | 0,00 % | Kymera Therapeutics auf Stifel-Forum: Schnellerer Entwicklungspfad für führenden Wirkstoffkandidaten | ||
| QIAGEN | 39,305 | +0,90 % | EQS-News: CPT GmbH: Warren Wise entschlüsselt Qiagens DNA | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise entschlüsselt Qiagens DNA
25.09.2026 / 18:15 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 29,850 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 17,690 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| IMMUNOVANT | 33,490 | 0,00 % | Immunovant (IMVT): One Trial Failure Doesn't Break the Bull Case | ||
| BEAM THERAPEUTICS | 24,230 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 285,34 | -0,11 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| CG ONCOLOGY | 69,69 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 76,81 | 0,00 % | Goldman Sachs startet Coverage für Tarsus Pharmaceuticals mit Kaufempfehlung |
Das Unternehmen DUALITY BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 21,600 Euro und damit -0,92 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.